<DOC>
	<DOCNO>NCT02200848</DOCNO>
	<brief_summary>This study subject diagnose recurrent relapse CLL/SLL . The purpose study test safety combination drug lenalidomide ibrutinib different dose level , combination drug rituximab . We want find effect , good and/or bad , patient CLL/SLL . The hypothesis study safe give three drug combination information learn trial use study 3 drug combination large future trial .</brief_summary>
	<brief_title>Phase I Study Lenalidomide , Rituximab Ibrutinib Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Treatment consist dose escalation lenalidomide ibrutinib fix dos rituximab . A small expansion cohort include 10 patient follow recommend phase II dose find .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Previously treat chronic lymphocytic leukemia small lymphocytic lymphoma require treatment No prior systemic treatment within 4 week enrollment No corticosteroid within 2 week prior study entry Measurable disease must present No concomitant anticancer therapy ECOG status &lt; /= 2 Patients HIV infection eligible Patients treat CLL SLL CNS eligible Nonpregnant nonnursing Life expectancy great 60 day Adequate bone marrow , kidney liver function No major surgery within 28 day minor surgery within 5 day start treatment History od Richter 's transformation History prior allogeneic transplant Radioimmunotherapy within 1 year enrollment Prior Bruton 's tyrosine kinase inhibitor lenalidomide History allergic reaction compound similar ibrutinib , lenalidomide rituximab hypersensitivity active uncontrolled autoimmune hemolytic anemia ITP Transfusiondependent thrombocytopenia bleed disorder Active hepatitis B C infection History know Human AntiChimeric Antibody positivity History erythema multiforme , toxic epidermal necrolysis , StevensJohnson syndrome History uncontrolled seizure Autoimmune disorder require active immunosuppression Stroke intracranial hemorrhage within last 6 month History congestive heart failure , myocardial infarction , unstable angina , uncontrolled arrhythmia Class 3 4 heart disease last 6 month No prior malignancy except treated curative intent active disease 3 year ; adequately treat nonmelanoma skin cancer cervical cancer situ use warfarin similar Vitamin K antagonists Unable swallow capsule disease significantly affect gastrointestinal function inhibit small intestine absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Rituximab</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
</DOC>